International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2026   Volume 16   Issue 3

Precision Phytopharmacology: Patient Stratification, Molecular Mechanisms, Exposure Modeling, and Response Prediction for Natural Product-Based Therapeutics
Download PDF


, ,
  1. Department of AI for Neurotransmitter Modulation by Plant Alkaloids, Faculty of Pharmacy, Utrecht University, Utrecht, Netherlands.
  2. Department of Computational Toxicology for Herbal Hepatotoxicity, Faculty of Pharmacy, University of Groningen, Groningen, Netherlands.
Citation
Vancouver
Van der Meer E, Jansen L, de Vries B. Precision Phytopharmacology: Patient Stratification, Molecular Mechanisms, Exposure Modeling, and Response Prediction for Natural Product-Based Therapeutics. Int J Pharm Phytopharmacol Res. 2026;16(3):66-79. https://doi.org/10.51847/OPLexbSKES
APA
Van der Meer, E., Jansen, L., & de Vries, B. (2026). Precision Phytopharmacology: Patient Stratification, Molecular Mechanisms, Exposure Modeling, and Response Prediction for Natural Product-Based Therapeutics. International Journal of Pharmaceutical And Phytopharmacological Research, 16(3), 66-79. https://doi.org/10.51847/OPLexbSKES
Download citation:   EndNote   RIS
Article Link:
Downloads: 29
Views: 96
Abstract

Natural product-based therapeutics present distinctive precision-pharmacology challenges because botanical identity, phytochemical composition, biological mechanisms, systemic exposure, patient characteristics, concomitant medications, and safety liabilities may vary simultaneously. This article proposes a precision phytopharmacology framework for organizing these sources of variability without implying that natural products can presently be personalized through unvalidated biomarkers or computational predictions. The framework begins with authenticated natural product identity and reproducible phytochemical characterization, followed by structured definition of patient context and development of testable stratification hypotheses. Molecular evidence is organized across candidate biomarkers, targets, pathways, bioactivity findings, network relationships, and mechanistic plausibility. Exposure modeling integrates bioavailability, absorption, distribution, metabolism, excretion, constituent-specific pharmacokinetics, physiologically based pharmacokinetic logic, and provisional exposure–response relationships where adequate evidence exists. Response and safety predictions are treated as research outputs requiring uncertainty estimation, calibration, external validation, and assessment of herb–drug interaction risk. Personalization is therefore restricted to hypothesis generation, research prioritization, validation planning, and identification of evidence gaps. It does not constitute individualized dosing, therapeutic selection, clinical decision support, or proof of clinical utility. The principal contribution is an integrated, safety-aware architecture that connects natural product quality, patient heterogeneity, molecular mechanisms, exposure variability, response hypotheses, expert review, and explicit treatment-claim boundaries within a single translational research framework.

Related articles:
Most viewed articles:
Naproxen in Pain and Inflammation – A Review
Vol 11 Issue 1, 2021 | Svetoslav Nikolaev Stoev
An Overview on Emulgel
Vol 9 Issue 1, 2019 | Sreevidya V.S
Volume 16
Issue 4
2026

Call for Papers
[email protected]
Issues
Associations
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2026 International Journal of Pharmaceutical and Phytopharmacological Research
Authors retain copyright of their article if they are accepted for publication.